Bridge Bank

Your growing life sciences company can benefit from committed; experienced support needed to bring your vision to market. Bridge Bank's Life Sciences Group works with companies from pre-clinical development and testing, through product launch and beyond. https://lnkd.in/gNa-cxqP

Wherever and however you’re spending this holiday season, we hope it’s a joyful conclusion to 2024.

Bridge Bank would like to wish you and your loved ones a Merry Christmas! Bridge Bank will be closed on December 25, 2024. We will reopen on December 26, 2024 to serve your needs.

In San Francisco for the J.P. Morgan Healthcare Conference? Connect with our experienced Life Sciences Bankers while you’re in town and hear how Bridge Bank can help you bring your vision to market. Request a meeting by completing our form here: https://bit.ly/41CkyFe. You can also reach out to Bill Wickline directly at bill.wickline@bridgebank.com.

The venture capital industry has been changing significantly in recent times. Those in the VC sector know that a strong banking partner, like Bridge Bank, can be an essential piece of the puzzle to enhance their success and help navigate the unexpected. Hear Drago Sipovic, Bridge Bank's Head of Equity Fund Resources, explain why Fund Finance should be backed by flexibility and ingenuity. https://lnkd.in/gaQdgpY9

Congratulations to our client EliseAI on their recent monumental achievement of reaching unicorn status after their $75 million Series D funding round! On the heels of the funding round, Brandon Echevarria, Chris Perkins and Dave Dailey in our Technology Banking Group worked with the company to increase their line of credit to $40 million. This increased facility will support the company’s ongoing growth initiatives. EliseAI is dedicated to building the world’s most advanced conversational AI platform with a focus on transforming industries that serve the most fundamental human needs, starting with housing and healthcare. EliseAI’s advanced suite of AI-powered solutions enables businesses to unlock significant operational efficiencies while increasing their ability to serve more people.

Mark Breneman, Jeff Brown and Jackson Perron recently worked with Insight M to provide them with a $10MM growth capital term loan to assist with their growth and expansion. Insight M is a consultative methane emissions management company that provides data, insight, analytics and mitigation strategies to help oil and gas companies reduce their emissions and protect their brands from public and regulatory scrutiny. Their evidence-based solutions empower their clients to achieve operational excellence in methane management and protecting the environment.

Bridge Bank was proud to host and sponsor the Big Ten Venture Summit at our Chicago office for the third year in a row. The Big Ten Venture Network represents the Venture and Angel groups at the various Big Ten Schools, plus The University of Chicago. This year’s conference had representation from 15 Universities who have invested in startups nationwide. Thank you, IU Ventures for organizing the event and Quarles & Brady LLP for their co-sponsorship. In addition to networking and benchmarking opportunities, summit participants heard from various panels and speakers including Bridge Bank’s own Ryan Dammeyer and Jennifer Morasca. Bridge Bank provides expert guidance and solutions to promising early-stage tech companies and helps them navigate growth, reach milestones and raise additional funds. 

Bill Wickline, Lan Zhu and Phil Ho , in our Life Sciences Group, have recently worked with Locus Biosciences, Inc. to provide the company with a $10,000,000 tranched term loan to help them achieve their growth objectives. Locus Biosciences is a cutting-edge precision medicine company leveraging artificial intelligence to develop engineered bacteriophage therapeutics. These innovative treatments precisely target and eliminate harmful bacteria while preserving the rest of the microbiome. Locus Biosciences is applying its groundbreaking platform to address infectious diseases and immunological conditions, including pioneering a novel therapy for Crohn’s disease.

In life sciences, success stories need to overcome regulatory hurdles and the unpredictability of both the lab and the market. We get it. From biotech to pharmaceutical companies to medical devices and diagnostics, our team knows life sciences and we’ve got solutions made for you.